SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Zscaler, Inc. engages in the provision of a cloud-based internet security platform. It offers Zero Trust Exchange, Zscaler Client Connector, Zscaler Internet Access, Zscaler Private Access, Zscaler B2B, Zscaler Cloud Protection, and Zscaler Digital Experience. The company was founded by Jagtar Singh Chaudhry and K. Kailash in September 2007 and is headquartered in San Jose, CA.

Zscaler Inc

Zscaler shares plummeted following a fiscal third-quarter earnings report that featured a guidance miss, leading to concerns over decelerating growth and increased capital expenditure. The community is sharply divided between investors panicking over management's narrative and leadership changes, and those attempting to buy the dip, with many debating if the company's valuation still holds as growth slows.

Digital Turbine, Inc. is a mobile growth platform that offers solutions for advertisers, publishers, carriers, and device original equipment manufacturers (OEMs). The firm operates through the On Device Solutions (ODS) and App Growth Platform (AGP) segments. The ODS segment generates revenue from the delivery of mobile application media or content to end users with solutions for all participants in the mobile application ecosystem that want to connect with end users and consumers who hold the device. This includes mobile carriers and device OEMs that participate in the app economy, app publishers and developers, and brands and advertising agencies. The AGP segment provides platforms that allow mobile app publishers and developers to monetize their monthly active users via display, native, and video advertising. The company was founded on November 6, 1998 and is headquartered in Austin, TX.

Digital Turbine Inc

Digital Turbine is trending as investors react to a positive earnings double-beat, strong guidance for fiscal year 2027, and a new strategic partnership with Databricks to bolster AI capabilities. The community is actively debating the company's turnaround potential, focusing on debt management and high short interest versus the firm's growth in mobile advertising and AI-driven infrastructure.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is surging after reaching a historic trillion-dollar market cap, fueled by an aggressive UBS price target hike and intensifying optimism surrounding the company's role as a critical AI infrastructure and memory supplier. While bulls are celebrating the massive year-to-date rally and potential for further gains, the community remains intensely divided between those betting on continued parabolic growth and others cautioning that the stock has become dangerously overheated.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is seeing significant volatility and increased interest driven by a combination of a technically oversold chart structure and speculative momentum regarding the company's Matrix-M adjuvant platform's potential use in emerging disease outbreaks. Community discourse is sharply divided between retail investors betting on a short squeeze or buyout potential and those frustrated by the company's leadership and persistent lack of clear communication regarding pipeline execution.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Sellas Life Sciences is trending as investors aggressively monitor the approaching 80th clinical trial event for its lead AML therapy, with the community intensely debating the company's data transparency and the potential for a transformative buyout. Enthusiastic supporters are pointing to recent executive messaging and institutional interest as signals of a major valuation shift, while vocal skeptics maintain caution regarding trial outcomes and historical transparency.

Groupon, Inc. engages in the global scaled two-sided marketplace that connects consumers to merchants. It operates through the North America and International geographical segments. The company was founded by Andrew D. Mason, Eric Paul Lefkofsky, and Bradley A. Keywell in October 2008 and is headquartered in Chicago, IL.

Groupon Inc

Groupon is experiencing significant upward momentum as investors highlight a textbook short squeeze setup characterized by extremely high short interest, a shrinking free float due to active buybacks, and significant dealer hedging activity around key strike prices. Community sentiment is overwhelmingly bullish, with traders drawing parallels to historic short squeezes and actively discussing the potential for a parabolic move as they aim to force institutional shorts to cover their positions.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bear 3X ETF

Direxion Daily Semiconductor Bear 3X Shares

Investors are actively debating the sustainability of the semiconductor sector's parabolic rally, with many retail traders experiencing significant losses while attempting to time a correction using the inverse leveraged ETF. The intense volatility and rapid price erosion of the symbol have sparked heated discussions about whether the industry is in a historic bubble or if the trend will continue to punish contrarian bets.

Sidus Space, Inc. is a space-as-a-service company. The firm focuses on commercial satellite design, manufacture, launch planning, mission operations and in-orbit support, and data collection with a vision to demonstrate space operations for new technologies, and deliver data and predictive analytics to both domestic and global customers. The company was founded by Carol M. Craig on July 17, 2012 and is headquartered in Merritt Island, FL.

Sidus Space Inc - Ordinary Shares - Class A

Sidus Space is trending as investors aggressively build positions in aerospace stocks ahead of the anticipated SpaceX IPO, with the community actively tracking its inclusion in the Russell 3000 and ongoing defense contract momentum. Sentiment remains highly bullish among long-term holders who are ignoring short-term volatility, while traders continue to focus on key technical breakouts and potential institutional accumulation.

Redwire Corp. manufactures and supplies space equipment. It offers critical space solutions and reliability components for the next generation space economy with IP for solar power generation and in-space 3D printing and manufacturing. It assists its customers in solving challenges of future space missions. The company was founded in 2020 and is headquartered in Jacksonville, FL.

Redwire Corporation

Redwire Corp

Redwire Corp is trending as retail traders drive momentum around the companys role in critical space infrastructure and NASA project participation, further fueled by anticipation surrounding the upcoming SpaceX IPO. The community is actively debating the potential for a short squeeze, with many long-term investors holding through volatility while others discuss profit-taking strategies and the broader re-rating of the aerospace sector.

Boston Scientific Corp. engages in the development, manufacture, and marketing of medical devices that are used in interventional medical procedures. It operates through the MedSurg and Cardiovascular segments. The MedSurg segment includes Endoscopy, Urology, and Neuromodulation. The Cardiovascular segment consists of Cardiology and Peripheral Interventions. The company was founded by John E. Abele and Pete Michael Nicholas on June 29, 1979 and is headquartered in Marlborough, MA.

Boston Scientific Corp.

Boston Scientific stock is under pressure as investors react to the company's agreement to acquire Penumbra for approximately $14.5 billion. While the community recognizes the strategic long-term value of expanding into the vascular and neurovascular markets, the immediate drop reflects concerns regarding the deal's size, potential dilution, and integration costs.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

TGTX Stock Rises 29% in 3 Months: Here's What You Should Know

TG Therapeutics gains on strong Briumvi sales growth, higher 2026 revenue guidance and advancing late-stage studies in RMS.

TGTX Q1 Earnings Miss, Sales Rise Y/Y, Stock Up on Raised 2026 View

TG Therapeutics misses Q1 earnings estimates, but strong Briumvi sales drive y/y revenues. Shares rise as the company raises 2026 revenue outlook.

TG Therapeutics (NASDAQ:TGTX) Reaches New 1-Year High  - Time to Buy?

TG Therapeutics (NASDAQ:TGTX) Reaches New 1-Year High - Here's Why...

TGTX Stock Hits Fresh 52-Week High – Here’s Why Retail Is Bullish Despite Q1 Earnings Miss

Equity

The company increased its U.S. sales forecast for Briumvi to $885 - $900 million, up from the earlier $825 - $850 million range

TG Therapeutics (TGTX) Q1 Earnings Lag Estimates

TG Therapeutics (TGTX) delivered earnings and revenue surprises of -26.88% and +2.81%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

TG Therapeutics Inc. Q1 Profit Climbs

(RTTNews) - TG Therapeutics Inc. (TGTX.OB) released earnings for its first quarter that Increased, from last year...

Precision BioSciences Reports First Quarter 2026 Financial Results and Provides Business Update

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies for high unmet need diseases, today reported financial results for the first quarter ended March 31, 2026, and provided a...

Pictet Asset Management Holding SA Trims Stock Position in TG Therapeutics, Inc. $TGTX

Pictet Asset Management Holding SA lowered its stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 9.2% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 1,461,048 shares of the biopharmaceutical company's stock after selling 148,503 sha...

TG Therapeutics, Inc. (NASDAQ:TGTX) Given Average Rating of "Moderate Buy" by Analysts

TG Therapeutics, Inc. (NASDAQ:TGTX - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the six ratings firms that are covering the stock, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold recommendation, three have given a buy reco...

Fortrea Holdings Inc. (FTRE) Reports Next Week: Wall Street Expects Earnings Growth

Fortrea Holdings Inc. (FTRE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

TG Therapeutics is a fully integrated, commercial stage, biotechnology company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI® (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features. For more information, visit www.tgtherapeutics.com, and follow us on X (formerly Twitter) @TGTherapeutics and on LinkedIn.

TGTX
TG Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Compact View

Poll

Latest TGTX News

TGTXTG Therapeutics Inc